WHO: Risk profile for AstraZeneca COVID vaccine "weighs heavily" in favour
Reuters
Published Mar 31, 2021 07:18AM ET
(Reuters) - The World Health Organization said on Wednesday it continues to monitor safety evidence reviews of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine but that the shot's benefit-risk profile "weighs heavily in favour of its use" amid reports of rare brain blood clots.
Alejandro Cravioto, chair of the WHO's Strategic Advisory Group of Experts (SAGE) on Immunization, told a briefing the panel was "comfortable" with the vaccine's use, since many of the countries using it have safety warning signal systems in place and are not reporting problems.
Many European countries briefly stopped using AstraZeneca's COVID-19 vaccine earlier this month while their drug safety authorities investigated rare cases of blood clots.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.